SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106-130.
  • 2
    Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol. 2004; 22: 86-92.
  • 3
    Messing EM. Urothelial tumors of the urinary tract. In: WalshPC, RetikAB, VaughanED, eds. Campbell's Urology. 8th ed. Philadelphia, PA: WB Saunders; 2002: 2732-2784.
  • 4
    Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol. 1991; 146: 316-318.
  • 5
    Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol. 1999; 161: 1120-1123.
  • 6
    Burnand KG, Boyd PJ, Mayo ME, Shuttleworth KE, Lloyd-Davies RW. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol. 1976; 48: 55-59.
  • 7
    Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993; 149: 749-752.
  • 8
    Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol. 1997; 79: 731-735.
  • 9
    Shuin T, Kubota Y, Noguchi S, et al. A phase II study of prophylactic intravesical chemotherapy with 4′-epirubicin in recurrent superficial bladder cancer: comparison of 4′-epirubicin and Adriamycin. Cancer Chemother Pharmacol. 1994; 35( suppl): S52-S56.
  • 10
    Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996; 155: 1233-1238.
  • 11
    Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003; 26: 1847-1851.
  • 12
    Hillman AL, Schwartz JS, Willian MK, et al. The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology. 1996; 47: 169-178.
  • 13
    Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health. 2005; 8: 149-156.
  • 14
    Medicare Current Beneficiary Survey. Baltimore, MD: Center for Medicare and Medicaid Services; 2000.
  • 15
    Rajala P, Liukkonen T, Raitanen M, et al. Transurethral resection with perioperative instillation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study–Finnbladder III. J Urol. 1999; 161: 1133-1135.
  • 16
    Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005; 43: 480-485.
  • 17
    Freeman JL, Zhang D, Freeman DH, Goodwin JS. An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol. 2000; 53: 605-614.
  • 18
    Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis. 2005; 46: 225-232.
  • 19
    Iezzoni L. Risk Adjustment for Measuring Health Care Outcomes. 3rd ed. Chicago, IL: Health Administration Press; 2003.
  • 20
    Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WFJr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol. 1989; 141: 22-29.
  • 21
    Herr HW, Klein EA, Rogatko A. Local BCG failures in superficial bladder cancer. A multivariate analysis of risk factors influencing survival. Eur Urol. 1991; 19: 97-100.
  • 22
    Herr HW, Wartinger DD, Fair WR, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol. 1992; 147: 1020-1023.
  • 23
    Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol. 1997; 15: 84-88.
  • 24
    Lamm DL, Blumenstein BA, Crawford ED, et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol. 1995; 1: 119-126.
  • 25
    Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am. 1992; 19: 573-580.
  • 26
    Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol. 2000; 163: 1124-1129.
  • 27
    Lamm DL. Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol. 2003; 21: 4259-4260.
  • 28
    Messing E, Kim KM, Sharkey F, et al. Randomized Prospective Phase III Trial of Difluoromethylornithine vs Placebo in Preventing Recurrence of Completely Resected Low Risk Superficial Bladder Cancer. J Urol. 2006; 176: 500-504.
  • 29
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002; 168: 1964-1970.
  • 30
    American Cancer Society. Statistics of Cancer Incidence 1997-2006. Available at: http://www.cancer.org/docroot/STT/stt_0_2004.asp?sitearea=STT&level=1 Accessed March 2009.
  • 31
    Herr HW. Intravesical therapy. A critical review. Urol Clin North Am. 1987; 14: 399-404.
  • 32
    Herr HW, Laudone VP, Badalament RA, et al. Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988; 6: 1450-1455.
  • 33
    Lamm DL. Bladder cancer: twenty years of progress and the challenges that remain. CA Cancer J Clin. 1998; 48: 263-268.
  • 34
    Lamm DL. Management of bladder cancer. J Urol. 2004; 171: 2482-2483.
  • 35
    Zincke H, Utz DC, Taylor WF, Myers RP, Leary FJ. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol. 1983; 129: 505-509.
  • 36
    Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006; 107: 2173-2179.
  • 37
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171: 2186-2190, quiz 2435.
  • 38
    Smith JAJr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999; 162: 1697-1701.
  • 39
    Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg C. Guidelines on bladder cancer. Eur Urol. 2002; 41: 105-112.
  • 40
    Madeb R, Messing EM. Long-term outcome of home dipstick testing for hematuria. World J Urol. 2008; 26: 19-24.
  • 41
    Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am. 2000; 27: 125-135, x.
  • 42
    McNaughton CM, Barry MJ, Zietman A, et al. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology. 2002; 60: 628-633.